

Applicant: Don Fishbein
Serial No.: 10/799,197
Filed: March 12, 2004
Page 2 of 10 of Amendment and SIDS

Amendments to the Claims:

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

1-29. (Canceled)

30. (Currently Amended) A method of promoting weight gain after weight loss resulting from post-burn catabolism in a patient which comprises administering to the patient ~~a therapeutically effective amount~~ 10mg of oxandrolone per day, up to 100mg of oxandrolone per day, for a period of three weeks, effective for promoting so as to promote weight gain in said patient wherein the weight gained is maintained at eight weeks after discontinuation of the oxandrolone administration.

31. (Canceled).

32. (Currently Amended) A method according to claim 31 wherein the amount of oxandrolone administered is about 80 mg per day.

33. (Currently Amended) A method according to claim 31 wherein the amount of oxandrolone administered is about 20 mg per day.

Applicant: Don Fishbein
Serial No.: 10/799,197
Filed: March 12, 2004
Page 3 of 10 of Amendment and SIDS

34. (Previously Presented) A method according to claim 31 wherein the amount of oxandrolone administered is about 10 mg per day.
35. (Canceled).
36. (Previously Presented) A method according to claim 30 wherein the oxandrolone is administered orally.
37. (Previously Presented) A method according to claim 30 wherein the oxandrolone is administered topically.
38. (Previously Presented) A method according to claim 30 wherein the oxandrolone is administered by injection.
39. (Previously Presented) A method according to claim 30 wherein the oxandrolone is in a solid dosage form.
40. (Previously Presented) A method according to claim 30 wherein the oxandrolone is in a liquid dosage form.
41. (Previously Presented) A method according to claim 30 wherein the oxandrolone is in a sustained-release formulation.
42. (Previously Presented) A method according to claim 30 wherein the oxandrolone is 17 α -methyl-17 β -hydroxy-2-oxa-5 α -androstan-3-one.

Applicant: Don Fishbein
Serial No.: 10/799,197
Filed: March 12, 2004
Page 4 of 10 of Amendment and SIDS

43. (Currently Amended) A method according to claim 30 further comprising administering during the period of oxandrolone administration a protein supplement to achieve a daily protein intake by the patient of 2.0 g/kg/day.
44. (Previously Presented) A method according to claim 30 wherein the weight gained comprises lean body mass.
45. (Canceled).
46. (Canceled).
47. (Previously Presented) A method according to claim 43, wherein the weight gained per unit time in the patient is double the weight gained by a patient suffering weight loss resulting from post-burn catabolism receiving the protein supplement but not the oxandrolone.